Printer Friendly

Compounds trigger tumor-cell suicide.

Cancer cells are a picture of conflict. Seemingly aware of the danger they themselves pose, these abnormal cells often try to commit suicide by activating destructive enzymes called caspases. But as if simultaneously compelled by a self-preservation instinct, tumor cells usually thwart this impulse using proteins that foil the caspases.

Now, a team of researchers has found compounds that inhibit a specific caspase inhibitor, thereby triggering the death of various tumor cells growing in laboratory dishes or in mice.

"It looks like cancers are poised to die if you take this roadblock away" says John C. Reed, president of the Burnham Institute in La Jolla, Calif., an independent biomedical research center.

Reed and his colleagues, who describe their work in the January Cancer Cell, knew from previous studies that a protein called X chromosome-linked inhibitor of apoptosis (XIAP) binds to and blocks the action of several different caspases. Numerous studies have shown that many kinds of cancer cells overproduce this caspase inhibitor, apparently to stymie the cellular-suicide program called apoptosis. Other researchers have identified compounds that prevent XIAP from inhibiting some of the caspases.

These blocking compounds don't directly kill cancer cells. Instead, they make the cells more susceptible to traditional chemotherapy drugs.

Using an automated system, Reed and his colleagues screened more than a million compounds for substances that thwart XIAP's inhibition of a particular caspase called caspase 3. This enzyme acts late in a cell's suicide program, so the investigators hypothesized that inhibiting XIAP's interaction with caspase 3 would guarantee a cancer cell's suicide.

The mass screening identified eight compounds-all belonging to a class of synthetic molecules called polyphenylureas--that block XIAP's action against caspase 3. Unlike previously known XIAP inhibitors, these compounds directly kill a broad range of solid-tumor cells and leukemia cells, Reed and his colleagues report. In their laboratory tests, the potency of these compounds compared favorably with that of already approved cancer drugs.

In separate tests, the investigators implanted human prostate or colon cancer cells into mice, permitted the cells to grow into tumors, and then injected the newfound compounds into the rodents. In postmortem analyses, the investigators found evidence that the compounds had killed cancer cells and slowed tumor growth.

Just as important, Reed and his colleagues saw no obvious sign of damage to normal cells and tissue. "We had concern about whether [inhibiting XIAP] would be a safe approach," he acknowledges.

The scientists have already developed a second generation of XIAP inhibitors that last longer in the body and have other improved biochemical properties. Reed notes that more safety tests are required.

Still, Reed and other researchers are excited about the strategy of hindering XIAP so that cancer cells will commit suicide.

"It's one of the most exciting molecular targets in the cancer pathway," says Lily Yang of Emory University School of Medicine in Atlanta, who is also developing XIAP inhibitors.
COPYRIGHT 2004 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Pushing Cancer over the Edge
Author:Travis, John
Publication:Science News
Date:Jan 24, 2004
Words:478
Previous Article:Papaya: glimpse of early sex chromosome.
Next Article:Slumber may fortify memory, stir insight.
Topics:


Related Articles
Drugs that fight cancer ... naturally.
Shedding light on cancer: doctors fight malignancies with photoactive dyes.
Cranking up cancer treatments: a bright future for growth factors.
Compound inhibits vessel growth, cancer.
Putting a tumor suppressor back to work.
Infectious Notion.
Tracking tumors: looking for early signs of a therapy's success.
Turmeric component kills cancer cells.
Medical maverick Tsuneo Kobayashi: a forerunner of cancer treatment and prevention.
ARQULE/KYOWA HAKKO KOGYO SIGN ARQ 197 ASIA LICENSE.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters